The Forgotten Majority
Unfinished Business in Cardiovascular Risk Reduction
Peter Libby, MD*
Donald W. Reynolds Cardiovascular Clinical Research Center, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts.
View larger version (17K):
[in a new window]
|
Figure 1 Percentage of patients experiencing major coronary events, according to several large outcomes studies. AFCAPS/TexCAPS = Air Force Coronary Atherosclerosis Prevention Study/Texas Coronary Atherosclerosis Prevention Study; CARE = Cholesterol And Recurrent Events trial; 4S = Scandinavian Simvastatin Survival Study; HPS = Heart Protection Study; LIPID = Long-term Intervention with Pravastatin in Ischemic Disease study; WOS = West of Scotland Coronary Prevention Study. Adapted from Kato H, et al. Am J Epidemiol 1973;97:372–85; HPS Collaborative Group. Lancet 2002;360:7–22; and LaRosa JC, et al. JAMA 1999;282:2340–6.
|
|
View larger version (10K):
[in a new window]
|
Figure 2 Cholesterol levels by species. Typical values of plasma low-density lipoprotein cholesterol (LDL-C) in several species, including human. Adapted from Dietschy JM, et al. J Lipid Res 1993;34:1637–59 and Ford ES, et al. Circulation 2003;107:2185–9.
|
|
View larger version (24K):
[in a new window]
|
Figure 3 Mean baseline serum cholesterol in the Seven Countries Study. Adapted from Menotti A, et al. Eur J Epidemiol 1993;9:527–36.
|
|
|
